Royal Bank Of Canada Unity Biotechnology, Inc. Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.4 - $4.27 $111 - $1,187	278 Added 20.07%	1,663 $0
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.29 $6,132 - $14,125	-10,950 Reduced 88.77%	1,385 $1,000
Q1 2022 May 16, 2022	BUY	$0.72 - $1.86 $7,920 - $20,460	11,000 Added 823.97%	12,335 $13,000
Q4 2021 Feb 14, 2022	SELL	$1.3 - $3.17 $1,378 - $3,360	-1,060 Reduced 44.26%	1,335 $2,000
Q3 2021 Nov 15, 2021	SELL	$2.91 - $4.5 $19,054 - $29,466	-6,548 Reduced 73.22%	2,395 $7,000
Q2 2021 Aug 16, 2021	BUY	$4.15 - $6.3 $37,113 - $56,340	8,943 New	8,943 $42,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $14M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.